Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 12
Submit an article Journal homepage
795
Views
20
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy

John HornbergerCedar Associates LLC, Menlo Park, CA, USA;Stanford University, Stanford, CA, USACorrespondence[email protected]
,
Rebecca ChienCedar Associates LLC, Menlo Park, CA, USA
,
Mark FriedmannColumbia University Mailman School of Public Health, New York, NY, USA
,
Leona HanBiomedical Ethics Research Unit, Mayo Clinic, Rochester, MN, USA
,
Ashwini ShewadeCedar Associates LLC, Menlo Park, CA, USA
,
Sacha Satram-HoangQ.D. Research, Inc., Granite Bay, CA, USA
&
Carolina ReyesGenentech, Inc., South San Francisco, CA, USA;University of California, San Francisco, San Francisco, CA, USA
 show all
Pages 2371-2377 | Received 17 Nov 2011, Accepted 12 May 2012, Published online: 12 Jun 2012

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Ziyan Chen, Yue Cheng, David DeRemer & Vakaramoko Diaby. (2021) Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 21:5, pages 923-941.
Read now
Gregory F. Guzauskas, Anthony Masaquel, Per-Olof Thuresson, Keith Dawson & David L. Veenstra. (2019) Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States. Leukemia & Lymphoma 60:7, pages 1668-1676.
Read now
Morag Meriel Griffin & Nick Morley. (2013) Rituximab in the treatment of non-Hodgkin's lymphoma – a critical evaluation of randomized controlled trials. Expert Opinion on Biological Therapy 13:5, pages 803-811.
Read now
Sonali M. Smith. (2012) Maintenance rituximab revisited: is it worth the cost?. Leukemia & Lymphoma 53:12, pages 2331-2332.
Read now

Articles from other publishers (16)

Nathan Fowler, Guifang Chen, Stephen Lim, Stephanie Manson, Qiufei Ma & Frank Li. (2023) reatment Patterns and Health Care Costs in Commercially Insured Patients with Follicular Lymphoma. Journal of Health Economics and Outcomes Research, pages 148-157.
Crossref
Caitlin Eichten, Qiufei Ma, Thomas E. Delea, May Hagiwara, Roberto Ramos, Şerban R. Iorga, Jie Zhang & Richard T. Maziarz. (2021) Lifetime Costs for Treated Follicular Lymphoma Patients in the US. PharmacoEconomics 39:10, pages 1163-1183.
Crossref
Gursharan K. Sohi, Jordan Levy, Victoria Delibasic, Laura E. Davis, Alyson L. Mahar, Elmira Amirazodi, Craig C. Earle, Julie Hallet, Ahmed Hammad, Rajan Shah, Nicole Mittmann & Natalie G. Coburn. (2021) The cost of chemotherapy administration: a systematic review and meta-analysis. The European Journal of Health Economics 22:4, pages 605-620.
Crossref
Neerav Monga, Jamie Garside, Binu Gurung, Joan Quigley, Peter O’Donovan, Christoph Tapprich, Loretta Nastoupil, Catherine Thieblemont & Christina Loefgren. (2020) Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews. PharmacoEconomics - Open 4:4, pages 575-591.
Crossref
Camille Golfier & Gilles Salles. (2020) Antibody Therapy Maintenance in Follicular Lymphoma. Hematology/Oncology Clinics of North America 34:4, pages 689-699.
Crossref
Shigeo Fuji. (2020) Answer to Simulation Analysis of Cost-Effectiveness in 2012 Has Finally Come in 2019. Journal of Clinical Oncology 38:5, pages 522-522.
Crossref
Amy K. Erbe, Wei Wang, Lakeesha Carmichael, Anna Hoefges, Bartosz Grzywacz, Patrick K. Reville, Erik A. Ranheim, Jacquelyn A. Hank, KyungMann Kim, Songwon Seo, Eneida A. Mendonca, Yiqiang Song, Vaishalee P. Kenkre, Fangxin Hong, Randy D. Gascoyne, Elisabeth Paietta, Sandra J. Horning, Jeffrey S. Miller, Brad Kahl & Paul M. Sondel. (2019) Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Scott F. HuntingtonGottfried von KeudellAmy J. DavidoffCary P. GrossSapna A. Prasad. (2018) Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. Journal of Clinical Oncology 36:33, pages 3307-3314.
Crossref
Gilles Salles, Martin Barrett, Robin Foà, Joerg Maurer, Susan O’Brien, Nancy Valente, Michael Wenger & David G. Maloney. (2017) Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Advances in Therapy 34:10, pages 2232-2273.
Crossref
Lucy Hui, Gottfried von Keudell, Rong Wang, Amer M. Zeidan, Steven D. Gore, Xiaomei Ma, Amy J. Davidoff & Scott F. Huntington. (2017) Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 123:19, pages 3763-3771.
Crossref
Lu Zhang, Michele Ghielmini, Bruce D. Cheson & Chaitra Ujjani. (2017) Pros and cons of rituximab maintenance in follicular lymphoma. Cancer Treatment Reviews 58, pages 34-40.
Crossref
Karen Lien, Matthew C. Cheung & Kelvin K.W. Chan. (2016) Adjusting for Drug Wastage in Economic Evaluations of New Therapies for Hematologic Malignancies: A Systematic Review. Journal of Oncology Practice 12:4, pages e369-e379.
Crossref
Jagpreet Chhatwal, Michael Mathisen & Hagop Kantarjian. (2015) Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer 121:19, pages 3372-3379.
Crossref
Qiushi Chen, Turgay Ayer, Loretta J. Nastoupil, Adam C. Rose & Christopher R. Flowers. (2015) Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Following First-Line Therapy in Patients with Follicular Lymphoma. Value in Health 18:2, pages 189-197.
Crossref
Nicoletta Martone, Carlo Lucioni, Silvio Mazzi & Valeria Fadda. (2014) Cost-Effectiveness Evaluation of Oncological Drugs Newly Marketed in Italy. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 1:2, pages GRHTA.5000182.
Crossref
Amruth R. Palla & Mehdi Hamadani. (2012) Rituximab maintenance versus retreatment in follicular lymphoma. Hematological Oncology 31:4, pages 171-178.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.